Karyopharm Therapeutics is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets in cancer. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.  For more information, visit Karyopharm.com.

85 Wells Ave Ste. 210
Newton, MA 02459

Patient Support Center:
Karyforward.com
1 877 KARY4WD (1 877 527 9493)

Medical Information: medicalinformation@karyopharm.com

Password: LLS21!

Please make sure the password is typed in ALL CAPS and includes the exclamation point.  Enter the email address that you used to register for the conference.